Video

Will Biosimilars Reduce Specialty Drug Spending?

Author(s):

Davy James, Managing Editor

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Related Videos
Related Content
Las Vegas strip, Aerial view
April 25th 2025

Asembia's AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Nasopharyngeal carcinoma -- Image credit: Matthieu | stock.adobe.com
April 24th 2025

FDA Approves Penpulimab-Kcqx for Indications in Nonkeratinizing Nasopharyngeal Carcinoma

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Hepatitis B virus blood test -- Image credit: gamjai | stock.adobe.com
April 24th 2025

Investigators Anticipate Hydronidone Will Be Beneficial for Liver Fibrosis in CHB

Gillian McGovern, Associate Editor
Image of kidneys without fibrosis -- Image credit: Itsaree | stock.adobe.com
April 24th 2025

Type 5 Collagen Linked to Kidney Scarring, Offers New Treatment Hope for Patients With CKD

Gillian McGovern, Associate Editor